Researchers from Oxford University have announced the full results of research into thromboembolic and thrombocytopenia blood clots following the vaccines of COVID-19 and this is the reason some countries have restricted the use of the Oxford-AstraZeneca vaccine. 

In the British Medical Journal, researchers have explained the findings with almost 29 million people who were vaccinated with the first dose of either Oxford-AstraZeneca ChAdOx1 Cov-19 vaccine or BNT162b2 mRNA Pfizer BioNTech vaccine. They mentioned that these vaccines are increased risks for the short time intervals and with the first dose showing vascular and hematological blood clots might lead to hospital and death. 

COVID 19, Not Vaccination, Presents Biggest Blood Clot: Research

Julia Hippisley-Cox, who is a professor at Oxford University of general practice and clinical Epidemiology, and the lead author of this research said, “People should know these things about the risks involved after taking COVID-19 vaccination and take help from medical if something happens. Also, be aware that risks are higher and can be for a longer time in case they become infected with the SARS-CoV-2”. 

COVID 19, Not Vaccination, Presents Biggest Blood Clot: Research

The impacts of infection of Coronavirus still require more study as experts believe that those who have suffered from quick blood clotting in veins are a result of infection and not vaccination. In fact, the vaccines help the body to prepare antibodies that can counter the infection spread but it has no role in creating such clots. It is a sheer job of virus only said one of the experts who have studied a variety of samples. 

The researchers note that all the risk involved in adverse blood clots which is substantially higher with a longer period for the infection from SARS-CoV-2 after the COVID-19 vaccine. All the COVID-19 vaccines which are currently used in many countries are tested in randomized trials. 

These are unlikely large enough for detecting even the rare and smallest blood clots. When these events are not covered, regulators may perform risk-benefit trials of the medications. to analyze the dangers of the unfavorable occasions whenever inoculated versus the advantages of aversion of the sickness—for this situation, COVID-19. 

In this paper, the group of creators from the University of Oxford, University of Leicester, Guys and St Thomas’ NHS Foundation Trust, the Intensive Care National Audit and Research Center, the London School of Hygiene and Tropical Medicine, the University of Cambridge, the University of Edinburgh and the University of Nottingham, analyzed paces of unfavorable occasions after inoculation with Pfizer-BioNTech and Oxford-AstraZeneca immunizations with paces of similar occasions after a positive SARS-CoV-2 test outcome. 

For this, they utilized regularly gathered electronic wellbeing records to assess the transient dangers (inside 28 days) of emergency clinic confirmation with thrombocytopenia, venous thromboembolism (VTE), and blood vessel thromboembolism (ATE), utilizing information gathered from across England between December 1, 2020, and April 24, 2021.

 Different results contemplated were cerebral venous sinus apoplexy (CVST), ischemic stroke, myocardial localized necrosis, and other uncommon blood vessel thrombotic occasions. 

“This study is very important as most studies being useful to have been potential biases and limited with small numbers. Records of electronic healthcare contain detailed recordings of vaccination, confounder, outcomes, and infections, which have provided a rich source of data and perform a full evaluation of such vaccines as compared to risks that are associated with COVID-19 disease. 

However, researchers believe that any biases are likely to be not changed with each vaccine and the comparison between all the vaccines might be affected. 

“On balance, this examination hence plainly highlights the significance of getting immunized to decrease the danger of these coagulating and draining results in people, and on account of the generous general medical advantage that COVID-19 immunizations offer,” said Aziz Sheikh.